Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Befovacimab in Severe Hemophilia A or B
NCT02571569Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2015
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of befovacimab in hemophilia A and hemophilia B (HB) (3 arms), sponsored by Bayer. Primary endpoints: Number of participants with adverse events up to 56 days, Plasma levels of anti-BAY1093884 antibodies at Day 56 and 2 more. Started Oct 2015; status: completed.
02
Drugs
befovacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02571569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571569.